Skip to main content
SpringerLink
Log in

Anti-Aβ antibody target engagement: commentary regarding Watt et al. Acta Neuropathol 127:803–810 (2014)

  • Correspondence
  • Published:
Acta Neuropathologica Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Adolfsson O, Pilhgren M, Toni N et al (2012) An effector-reduced anti-beta-amyloid (Abeta) antibody with unique abeta binding properties promotes neuroprotection and glial engulfment of Abeta. J Neurosci 32(28):9677–9689

    Article  PubMed  CAS  Google Scholar 

  2. Bard F, Barbour R, Cannon C et al (2003) Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer’s disease-like neuropathology. Proc Natl Acad Sci USA 100(4):2023–2028

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  3. Bjerke M, Portelius E, Minthon L et al (2010) Confounding factors influencing amyloid beta concentration in cerebrospinal fluid. Int J Alzheimers Dis 2010:1–11, Article ID 986310. doi:10.4061/2010/986310

  4. Black RS, Sperling RA, Safirstein B et al (2010) A single ascending dose study of bapineuzumab in patients with Alzheimer disease. Alzheimer Dis Assoc Disord 24(2):198–203

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  5. Blennow K, Zetterberg H, Rinne JO et al (2012) Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch Neurol 69:1002–1010

    Article  PubMed  Google Scholar 

  6. DeMattos RB, Bales KR, Cummins DJ et al (2001) Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci 98(15):8850–8855

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  7. DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM (2002) Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer’s disease. Science 295(5563):2264–2267

    Article  PubMed  CAS  Google Scholar 

  8. DeMattos RB, Bales KR, Parsadanian M et al (2002) Plaque-associated disruption of CSF and plasma amyloid-β (Aβ) equilibrium in a mouse model of Alzheimer’s disease. J Neurochem 81:229–236

    Article  PubMed  CAS  Google Scholar 

  9. DeMattos RB, O’Dell MA, Parsadanian M et al (2002) Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer’s disease. PNAS 99(16):10843–10848

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  10. Doody RS, Thomas RG, Farlow M et al (2014) Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med 370(4):311–321

    Article  PubMed  CAS  Google Scholar 

  11. Farlow M, Arnold SE, van Dyck CH et al (2012) Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease. Alzheimers Dement 8(4):261–271

    Article  PubMed  CAS  Google Scholar 

  12. Gelfanova V, Higgs RE, Dean RA et al (2007) Quantitative analysis of amyloid-beta peptides in cerebrospinal fluid using immunoprecipitation and MALDI-Tof mass spectrometry. Brief Funct Genomic Proteomic 6(2):149–158

    Article  PubMed  CAS  Google Scholar 

  13. Kalback W, Watson MD, Kokjohn TA et al (2002) APP transgenic mice Tg2576 accumulate Abeta peptides that are distinct from the chemically modified and insoluble peptides deposited in Alzheimer’s disease senile plaques. Biochemistry 41(3):922–928

    Article  PubMed  CAS  Google Scholar 

  14. Kawarabayashi T, Younkin LH, Saido TC et al (2001) Age-dependent changes in brain, CSF, and plasma amyloid & #x03B2; protein in the Tg2576 transgenic mouse model of Alzheimer’s disease. J Neurosci 21(2):372–381

    PubMed  CAS  Google Scholar 

  15. Lachno DR, Evert BA, Vanderstichele H et al (2013) Validation of assays for measurement of amyloid-beta peptides in cerebrospinal fluid and plasma specimens from patients with Alzheimer’s disease treated with solanezumab. J Alzheimers Dis 34(4):897–910

    PubMed  CAS  Google Scholar 

  16. Legleiter J, Czilli DL, Gitter B et al (2004) Effect of different anti-Aβ antibodies on Aβ fibrillogenesis as assessed by atomic force microscopy. J Mol Biol 335(4):997–1006

    Article  PubMed  CAS  Google Scholar 

  17. Racke MM, Boone LI, Hepburn DL et al (2005) Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J Neurosci 25(3):629–636

    Article  PubMed  CAS  Google Scholar 

  18. Seubert P, Vigo-Pelfrey C, Esch F et al (1992) Isolation and quantification of soluble Alzheimer’s β-peptide from biological fluids. Nature 359:325–327

    Article  PubMed  CAS  Google Scholar 

  19. Shaw LM, Vanderstichele H, Knapik-Czajka M et al (2011) Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol 121(5):597–609

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  20. Siemers ER, Friedrich S, Dean RA et al (2010) Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease. Clin Neuropharmacol 33(2):67–73

    Article  PubMed  CAS  Google Scholar 

  21. Watt AD, Crespi GAN, Down RA et al (2014) Do current therapeutic anti-Aβ antibodies for Alzheimer’s disease engage the target? Acta Neuropathol 127:803–810

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

ES, RAD, RBD, and MLH are full time employees and minor stock holders at Eli Lilly and Company. KB, LMS, and DMH have served as consultants to Eli Lilly and Company. In addition, Washington University and DMH may receive income based on a license to Eli Lilly and Company of intellectual property related to solanezumab.

Author information

Authors and Affiliations

  1. Eli Lilly and Company, Indianapolis, IN, USA

    Eric Siemers, Robert A. Dean & Ronald B. DeMattos

  2. Eli Lilly and Company, Erl Wood, Surrey, UK

    Michael L. Hutton

  3. Clinical Neurochemistry Lab. Dept. of Neuroscience and Physiology, University of Gothenburg, Mölndal Campus, Gothenburg, Sweden

    Kaj Blennow

  4. Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

    Leslie M. Shaw

  5. Department of Neurology, Washington University, St. Louis, MO, USA

    David M. Holtzman

Authors
  1. Eric Siemers
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert A. Dean
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ronald B. DeMattos
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michael L. Hutton
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kaj Blennow
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Leslie M. Shaw
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. David M. Holtzman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eric Siemers.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Siemers, E., Dean, R.A., DeMattos, R.B. et al. Anti-Aβ antibody target engagement: commentary regarding Watt et al. Acta Neuropathol 127:803–810 (2014). Acta Neuropathol 128, 609–610 (2014). https://doi.org/10.1007/s00401-014-1332-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00401-014-1332-9

Keywords

Search

Navigation